Prestige Biologics signs ₩15.5bn commercial API manufacturing supply contract

Prestige Biologics · KOSDAQ · 334970 · Nov 12, 2026 · Supply contracts

Prestige Biologics Co., Ltd. filed a supply contract dated Nov 12, 2026 for commercial active pharmaceutical ingredient contract manufacturing, with a contract amount of ₩15.5bn. The filing reports the contract as 58.1% of revenue. The contract period runs from Nov 12, 2026 to Dec 31, 2027.

Key facts

Contract nameCommercial active pharmaceutical ingredient (API) contract manufacturing agreement
Contract amount₩15.5bn
% of revenue (as reported)58.1%
Period startNov 12, 2026
Period endDec 31, 2027

Comparison

Amount as % of prior-year revenue (calculated)123.6%
Revenue 2025₩12.5bn
Revenue 2024₩2.2bn
Revenue 2023₩1.7bn

Context

The contract amount is reported as 58.1% of the company's revenue. By our calculation, the ₩15.5bn amount is 123.6% of FY2025 revenue of ₩12.5bn. The filing does not describe any change to the share count or any share issuance.

Key metrics

Supply contracts

Supply contracts, last 12 months₩39.2bn As of Nov 12, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Supply contracts vs prior-year revenue312.7% As of Nov 12, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)